Skip to content 
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. more
| Time Frame | XTLB | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -17.28% | -1.08% | -1.38% |
| 1-Month Return | -17.28% | -0.47% | -1.81% |
| 3-Month Return | -5.99% | 2.13% | 1.38% |
| 6-Month Return | -37.45% | 17.04% | 5.68% |
| 1-Year Return | -46.68% | 6.56% | 11.74% |
| 3-Year Return | -28.04% | 16.78% | 65.15% |
| 5-Year Return | -76.65% | 34.34% | 73.68% |
| 10-Year Return | -85.25% | 137.88% | 260.03% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 28.00K | 1.47M | (459.00K) | - | 451.00K | [{"date":"2020-12-31","value":1.91,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-31.31,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":30.76,"profit":true}] |
| Cost of Revenue | 1.00K | 1.00K | 1.00K | - | 448.00K | [{"date":"2020-12-31","value":0.22,"profit":true},{"date":"2021-12-31","value":0.22,"profit":true},{"date":"2022-12-31","value":0.22,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Profit | (1.00K) | (1.00K) | (1.00K) | - | 3.00K | [{"date":"2020-12-31","value":-33.33,"profit":false},{"date":"2021-12-31","value":-33.33,"profit":false},{"date":"2022-12-31","value":-33.33,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Margin | (3.57%) | (0.07%) | 0.22% | - | 0.67% | [{"date":"2020-12-31","value":-536.9,"profit":false},{"date":"2021-12-31","value":-10.25,"profit":false},{"date":"2022-12-31","value":32.75,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Expenses | 948.00K | 1.03M | 880.00K | 765.00K | 2.17M | [{"date":"2020-12-31","value":43.59,"profit":true},{"date":"2021-12-31","value":47.4,"profit":true},{"date":"2022-12-31","value":40.46,"profit":true},{"date":"2023-12-31","value":35.17,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Income | (948.00K) | (1.03M) | (880.00K) | (765.00K) | (2.17M) | [{"date":"2020-12-31","value":-94800000,"profit":false},{"date":"2021-12-31","value":-103100000,"profit":false},{"date":"2022-12-31","value":-88000000,"profit":false},{"date":"2023-12-31","value":-76500000,"profit":false},{"date":"2024-12-31","value":-217200000,"profit":false}] |
| Total Non-Operating Income/Expense | (1.99M) | 1.47M | (443.00K) | (1.04M) | 963.00K | [{"date":"2020-12-31","value":-135.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-30.16,"profit":false},{"date":"2023-12-31","value":-71.14,"profit":false},{"date":"2024-12-31","value":65.55,"profit":true}] |
| Pre-Tax Income | (2.95M) | 435.00K | (1.35M) | (1.78M) | (1.16M) | [{"date":"2020-12-31","value":-679.08,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-309.89,"profit":false},{"date":"2023-12-31","value":-409.66,"profit":false},{"date":"2024-12-31","value":-265.98,"profit":false}] |
| Income Taxes | (166.00K) | (1.47M) | 468.00K | (167.89K) | (130.00K) | [{"date":"2020-12-31","value":-35.47,"profit":false},{"date":"2021-12-31","value":-313.25,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-35.87,"profit":false},{"date":"2024-12-31","value":-27.78,"profit":false}] |
| Income After Taxes | (2.79M) | 1.90M | (1.82M) | (1.61M) | (1.03M) | [{"date":"2020-12-31","value":-146.66,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.53,"profit":false},{"date":"2023-12-31","value":-84.91,"profit":false},{"date":"2024-12-31","value":-54.02,"profit":false}] |
| Income From Continuous Operations | (782.00K) | 435.00K | (1.35M) | (2.25M) | (1.03M) | [{"date":"2020-12-31","value":-179.77,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-309.89,"profit":false},{"date":"2023-12-31","value":-516.32,"profit":false},{"date":"2024-12-31","value":-236.09,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (782.00K) | 435.00K | (1.35M) | (1.78K) | (1.03M) | [{"date":"2020-12-31","value":-179.77,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-309.89,"profit":false},{"date":"2023-12-31","value":-0.41,"profit":false},{"date":"2024-12-31","value":-236.09,"profit":false}] |
| EPS (Diluted) | (0.01) | 0.24 | (0.33) | (0.33) | (0.11) | [{"date":"2020-12-31","value":-2.68,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-135.19,"profit":false},{"date":"2023-12-31","value":-135.11,"profit":false},{"date":"2024-12-31","value":-46.88,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| XTLB | |
|---|---|
| Cash Ratio | 0.52 |
| Current Ratio | 0.61 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| XTLB | |
|---|---|
| ROA (LTM) | -240.56% |
| ROE (LTM) | -577.13% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| XTLB | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.36 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.64 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| XTLB | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 8.48 |
| P/B | 1.90 |
| EV/R | 9.03 |
| EV/Ebitda | 16.88 |
| PEG | NM |
XTL Biopharmaceuticals Ltd ADR (XTLB) share price today is $0.8914
Yes, Indians can buy shares of XTL Biopharmaceuticals Ltd ADR (XTLB) on Vested. To buy
Yes, you can purchase fractional shares of XTL Biopharmaceuticals Ltd ADR (XTLB) via the Vested app. You can start investing in XTL Biopharmaceuticals Ltd ADR (XTLB) with a minimum investment of $1.
You can invest in shares of XTL Biopharmaceuticals Ltd ADR (XTLB) via Vested in three simple steps:
The 52-week high price of XTL Biopharmaceuticals Ltd ADR (XTLB) is $2.57. The 52-week low price of XTL Biopharmaceuticals Ltd ADR (XTLB) is $0.53.
The price-to-earnings (P/E) ratio of XTL Biopharmaceuticals Ltd ADR (XTLB) is
The price-to-book (P/B) ratio of XTL Biopharmaceuticals Ltd ADR (XTLB) is 1.90
The dividend yield of XTL Biopharmaceuticals Ltd ADR (XTLB) is 0.00%
The market capitalization of XTL Biopharmaceuticals Ltd ADR (XTLB) is $8.21M
The stock symbol (or ticker) of XTL Biopharmaceuticals Ltd ADR is XTLB
Consider the share price of XTL Biopharmaceuticals Ltd ADR as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether XTL Biopharmaceuticals Ltd ADR has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in XTL Biopharmaceuticals Ltd ADR shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the XTL Biopharmaceuticals Ltd ADR stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of XTL Biopharmaceuticals Ltd ADR and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that XTL Biopharmaceuticals Ltd ADR stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
